KBA 1704
Alternative Names: KBA-1704Latest Information Update: 19 Dec 2023
At a glance
- Originator Kling Biotherapeutics
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Desmoglein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 15 Dec 2023 Early research in Cancer in Netherlands (Parenteral) prior to December 2023 (Kling Biotherapeutics pipeline, December 2023)